市場調查報告書
商品編碼
997421

癌症/腫瘤分析的全球市場

Cancer/Tumor Profiling

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 239 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球癌症/腫瘤分析的市場規模,預計在分析期間(2020年∼2027年)將以9.3%的年複合成長率增長,從2020年的62億美元,到2027年達到116億美元。

本報告所分析的市場區隔之一的免疫測量部門,在分析期間中預計將以9.1%的年複合成長率增長,達到36億美元。

本報告提供全球癌症/腫瘤分析市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Caris Life Sciences
  • Genomic Health, Inc.
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Oxford Gene Technology
  • Qiagen NV
  • Ribomed Biotechnologies, Inc.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:44公司
目錄
Product Code: MCP10868

Abstract:

Global Cancer/Tumor Profiling Market to Reach $11.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Cancer/Tumor Profiling estimated at US$6.2 Billion in the year 2020, is projected to reach a revised size of US$11.6 Billion by 2027, growing at a CAGR of 9.3% over the analysis period 2020-2027. Immunoassays, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$3.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hybridization segment is readjusted to a revised 9.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 8.7% CAGR

The Cancer/Tumor Profiling market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 8.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Next Generation Sequencing Segment to Record 10.1% CAGR

In the global Next Generation Sequencing segment, USA, Canada, Japan, China and Europe will drive the 10.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$864.8 Million in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.

Select Competitors (Total 44 Featured) -

  • Caris Life Sciences
  • Genomic Health, Inc.
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Oxford Gene Technology
  • Qiagen NV
  • Ribomed Biotechnologies, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Cancer/Tumor Profiling: Market Overview & Outlook
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Cancer Worldwide: Primary Growth Driver
    • EXHIBIT 1: Cancer Rates (100,000 People) in Select Countries: 2021
    • EXHIBIT 2: Estimated New Cancer Cases & Deaths in the US by Sex: 2020
    • EXHIBIT 3: Estimated Number of New Cancer Cases in Men by Cancer Type: 2020
    • The United States: Characterized by Higher Incidence of Cancer
    • EXHIBIT 4: Estimated New Cancer Cases & Deaths in the US by Sex: 2020
    • EXHIBIT 5: Estimated New Cases for Selected Cancers in the US by State: 2020
    • Enhanced Use of Biomarkers in Tumor Profiling Bodes Well
    • Cancer Research & Funding Initiatives Augment Market Prospects
    • Growing Role of Personalized Medicine Augurs Well
    • Advances in Point-of-Care Cancer Diagnostics to Accelerate Uptake
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Melanoma Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Clinical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 40: World Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: World 15-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 43: USA Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 46: USA Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: USA Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: USA 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 49: USA Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: USA Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: USA 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 52: Canada Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Canada Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Canada 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 55: Canada Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Canada Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Canada 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 58: Canada Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Canada Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Canada 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 61: Japan Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Japan Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Japan 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 64: Japan Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Japan Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Japan 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 67: Japan Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Japan Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Japan 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 70: China Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: China Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: China 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 73: China Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: China Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: China 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 76: China Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: China Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: China 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 79: Europe Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 80: Europe Historic Review for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Europe 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 82: Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 85: Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 88: Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 91: France Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: France Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: France 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 94: France Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: France Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: France 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 97: France Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: France Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: France 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 100: Germany Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Germany Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Germany 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 103: Germany Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Germany Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Germany 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 106: Germany Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Germany Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Germany 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 109: Italy Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Italy Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Italy 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 112: Italy Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Italy Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Italy 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 115: Italy Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Italy Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Italy 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 118: UK Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: UK Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: UK 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 121: UK Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: UK Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: UK 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 124: UK Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: UK Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: UK 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 127: Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Rest of Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 130: Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 133: Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Rest of Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 136: Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Asia-Pacific Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 139: Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Asia-Pacific Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 142: Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Asia-Pacific Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 145: Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Rest of World Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
    • TABLE 148: Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Rest of World Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
    • TABLE 151: Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Rest of World Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44